Determining a Tolerable Dose of Primaquine in G6PD-deficient Persons Without Malaria in Mali
Status:
Completed
Trial end date:
2016-01-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to determine the highest tolerable dose of primaquine within
0.75 mg/kg. A tolerable dose is defined as one in which:
- Two or fewer participants (< 30%) experience hemolysis;
- No participant experiences a drug-related serious adverse event; and
- No participant requires a blood transfusion.
Phase:
Phase 1/Phase 2
Details
Lead Sponsor:
University of California, San Francisco
Collaborators:
Bill and Melinda Gates Foundation Malaria Research and Training Center, Bamako, Mali Radboud University University of Mississippi Medical Center